Staffan Encrantz

Director Staffan Encrantz buys 14,100 shares of SGHT at $4.88, now trading -48.2% from 52-week high; prior same-ticker buys largely underperformed.

Encrantz purchased 14,100 shares at $4.88 on 2026-06-10, increasing his holdings to 1.43M shares. The stock currently trades at $4.79, down 48.2% from its 52-week high of $9.24, and has declined 2.8% over the past 30 days despite a 90-day gain of 30.5%. Notably, Encrantz's prior trades at SGHT have shown weak timing: of 5 prior buys at this ticker, only 1 was well-timed at the 90-day mark, with the most recent purchase (2025-12-16) experiencing a -55.0% 90-day decline. This purchase arrives as the company remains unprofitable (net income of $-13.0M in the latest quarter) with contracting annual revenue growth of -3.1%, creating a backdrop where the insider's accumulation pattern at this ticker has not reliably preceded price appreciation.

Director Staffan Encrantz purchases 13,958 shares of SGHT at $8.31; stock has gained 129.4% over 90 days amid unprofitable operations.

Director Staffan Encrantz purchased 13,958 shares at $8.31 on 2025-12-16, increasing his holdings from 1.38M to 1.39M shares. The purchase occurs within a volatile 90-day window where SGHT has gained 129.4%, though the stock currently trades at $8.26, 3.5% below its 52-week high of $8.56. His cross-ticker track record shows strong performance (78.95% 90-day win rate, +25.1% avg 90d return), but his same-ticker history at SGHT is mixed: only 2 of 5 prior buys achieved positive 90-day returns, with the most recent June 2025 purchases showing mixed near-term results. The company remains unprofitable with negative $8.2M annual net income and flat annual revenue growth (-1.5%), raising questions about the fundamental drivers of recent price appreciation and whether the insider's conviction extends to the company's operational outlook or reflects market momentum.

Director Encrantz Staffan bought 90,525 shares over 3 days at blended $4.22; holds 1,377,964 post-transaction.

Encrantz Staffan, a director at the unprofitable Sight Sciences, made 3 separate purchases totaling 90,525 shares for $381,957.97 over June 4–6, 2025, raising his holdings to 1.38M shares (+7.0% from pre-transaction levels). The buys occurred at $4.17, $4.24, and $4.22—prices near the current market price of $4.20—while the stock is down 49.5% from its 52-week high of $8.31 yet up 46.8% over the trailing 30 days and 78.0% over 90 days. His cross-ticker track record shows strong performance (91.67% win rate on buys, +46.5% avg 30d return, +55.6% avg 90d return), but his 5 most recent prior purchases at this same ticker (May 28–June 3) remain too recent to assess outcomes. The company reported net income of $-14.2M against $17.5M quarterly revenue, indicating ongoing losses and raising questions about the sustainability of the recent price recovery that has characterized the buying window.

Director Encrantz Staffan bought 98,782 shares across 3 trades (May 30–June 3) at blended $3.81, increasing holdings 8.5% to 1,256,487 shares

Encrantz Staffan, a director at Sight Sciences, executed 3 separate purchases totaling 98,782 shares for $376,429.44 over a four-day window at an average price of $3.81 per share. The stock has since risen 31.8% over 30 days and 66.1% over 90 days from the transaction dates, and currently trades at $4.02, up from the 52-week low of $2.09 but still -51.6% from the 52-week high of $8.31. Encrantz's cross-ticker track record shows 15 prior buys with a 91.67% win rate at the 90-day mark, though at this specific ticker (SGHT), prior trades have been mixed—a November 2024 buy-and-sell pair both showed -4.3% and -25.5% returns at 30 and 90 days, with 1 of 2 prior same-ticker trades well-timed at the 90-day mark. The company remains unprofitable (latest quarter net income: $-14,154,000.00) with near-flat annual revenue growth of -1.5%, and the market cap is $207.8M.

Director Encrantz Staffan purchases 128,189 shares over 3 days at blended avg $3.52, raising holdings to 1,157,705 shares; SGHT -57.6% from 52-week high.

Director Encrantz Staffan executed 3 separate purchases totaling 128,189 shares for $451,734.06 over consecutive days (May 27–29, 2025) at prices ranging from $3.44 to $3.59, increasing his stake by 12.5% to 1,157,705 shares. The transaction occurred as the stock trades 57.6% below its 52-week high of $8.31, though recent momentum has been positive (30-day +11.8%, 90-day +32.8%). At the same ticker, prior trades show mixed outcomes: four of five recent transactions were well-timed at the 90-day mark, but his most recent SGHT buy (November 2024) deteriorated 25.5% over 90 days. The company remains unprofitable with a net loss of $14,154,000.00 against quarterly revenue of $17,508,000.00 and flat annual revenue growth (-1.5%). The scale of this purchase—increasing holdings by over 128K shares—combined with the 12-month low pricing context warrants observation of whether this accumulation signals confidence at depressed valuations or reflects opportunistic positioning ahead of potential operational inflection.

Director Encrantz Staffan executes matched buy-sell of 551,802 shares at $3.73 on same day; holds 4,573,920 shares post-transaction.

Encrantz Staffan simultaneously purchased and sold 551,802 shares at $3.73 on 2024-11-21, resulting in zero net change to his position. This appears to be an exercise of options or conversion of restricted stock units into common shares, followed by an immediate market sale to fund the exercise cost or for tax withholding purposes. The transaction does not reflect a discretionary buy or sell decision: the purchase and sale prices are identical, executed on the same day, and the volumes match precisely, which is characteristic of option exercises or RSU conversions. His post-transaction holding of 4,573,920 shares remains substantial. The stock trades at $3.76 currently, down 54.8% from the 52-week high and down 33.4% over 30 days, but Encrantz's exercise activity carries no conviction signal—it is a mechanical cash-neutral transaction common to equity compensation events. Investors should not interpret this as a strategic buy or sell by the insider.